02:46 AM EST, 11/13/2026 (MT Newswires) -- Galderma's (GALD.SW) Restylane Shaype received approval in Mexico for temporary chin augmentation and improved jawline definition, marking its first global approval for jawline enhancement. The approval adds to existing authorizations for chin augmentation in markets including Europe, Brazil, Canada, and Thailand, according to a Friday release. The Swiss dermatology group describes Restylane Shaype as a hyaluronic acid injectable designed to provide structural enhancement without surgery. It said a clinical study found the treatment improved jawline definition compared with no treatment, with improvements lasting up to two years.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.